A Hagemeijer

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson et al. · European Journal of Cancer · 2004 · 442 citations

Medicine, Molecular Medicine, Oncology +14

Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.

Marieke von Lindern, Sjozèf van Baal, J. Wiegant et al. · Molecular and Cellular Biology · 1992 · 395 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies".

David Grimwade, Andrea Biondi, Julien Mozziconacci et al. · PubMed · 2000 · 319 citations

Medicine, Hematology, Oncology +13

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

Bob Löwenberg, Stefan Suciu, E Archimbaud et al. · Journal of Clinical Oncology · 1998 · 288 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Michael Lübbert, Björn Rüter, Rainer Claus et al. · Haematologica · 2011 · 231 citations · Full text

Medicine, Oncology, Pharmacology +17